✦ LIBER ✦

Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study

✍ Scribed by Van Cutsem, E; Dirix, L; Van Laethem, J-L; Van Belle, S; Borner, M; Gonzalez Baron, M; Roth, A; Morant, R; Joosens, E; Gruia, G

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Multicentre phase II study using increas

✍ Jacqueline Duffour; Sophie Gourgou; Françoise Desseigne; Charles Debrigode; Laur 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 289 KB

Results of a phase II study combining, w

✍ Gamelin, E.; Jacob, J.; Boisdron, M.; Burtin, P.; Dorval, E.; Berger, V.; Fermen 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 168 KB

A phase II study of FOLFIRI-3 (double in

✍ Louvet, C; de Gramont, A; Mabro, M; Artru, P; André, T; Flesch, M; Maindrault-Go 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 99 KB

Capecitabine plus Irinotecan (XELIRI reg

✍ Erik Skof; Martina Rebersek; Zvezdana Hlebanja; Janja Ocvirk 📂 Article 📅 2009 🏛 BioMed Central 🌐 English ⚖ 288 KB

OP4. Cost-effectiveness of Irinotecan (C

✍ G Blijham; C Schmitt; P Aussage; B Henry-Launois; B Jolain; P Hérait 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 164 KB

A phase II study of irinotecan (CPT-11)

✍ Rosati, G.; Tucci, A.; Rinaldi, A.; Colarusso, D.; Rossi, A.; Pizza, C.; Manzion 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 163 KB